Concordia Fund

Advanz Pharma, formerly known as Concordia Healthcare, is a global specialty pharmaceutical company focused on the acquisition, commercialization, and optimization of complex medicines. The company operates a diverse portfolio of legacy and specialty products across therapeutic areas such as endocrinology, ophthalmology, and critical care. Advanz Pharma primarily grows through a buy-and-build strategy, acquiring established brands and niche medicines to expand its international footprint. Following a significant financial restructuring and rebranding in 2018, the company was eventually acquired by Nordic Capital in 2021. Today, it continues to provide essential medicines to patients across Europe and other international markets.